论文部分内容阅读
目的:探讨抗结核治疗对艾滋病(AIDS)合并肺结核的治疗效果与CD4+淋巴细胞的相关性。方法:选择我院收治的AIDS合并患肺结核患者68例,对其采取(2个月强化期四联异烟肼+利福平+吡嗪酰胺+乙胺丁醇/4个月巩固期异烟肼+利福平,即:2HERE/4HR)抗结核治疗,于治疗前及治疗后1个月、3个月及6个月采集新鲜静脉血,通过流式细胞术对CD4+淋巴细胞进行检测。结果:抗结核治疗后,患者CD4+淋巴细胞数量均有不同程度的提升。治疗结束后,患者症状、病灶吸收及痰菌转阴情况与原CD4+数量具有相关性,即CD4+数量低于100个/μL时,患者治疗效果不佳,而高于200个/μL时,治疗效果显著。结论:针对AIDS合并肺结核患者采取抗结核治疗,疗效显著,可以明显改善患者的临床症状,延长其存活时间。
Objective: To investigate the therapeutic effect of anti-TB therapy on AIDS complicated with pulmonary tuberculosis and its correlation with CD4 + lymphocytes. Methods: Sixty-eight AIDS patients with tuberculosis admitted to our hospital were enrolled in this study. They were randomly divided into 4 groups: Isoniazid + Rifampicin + Pyrazinamide + Ethambutol / 4 months consolidation period Hydrazine + rifampicin, ie, 2HERE / 4HR) anti-TB therapy. Fresh venous blood was collected before treatment, 1 month, 3 months and 6 months after treatment, and CD4 + lymphocytes were detected by flow cytometry. Results: After anti-TB treatment, the number of CD4 + lymphocytes in patients increased to some extent. After the treatment, the patient’s symptoms, lesion absorption and sputum negatives were correlated with the amount of CD4 +, ie, the treatment effect was poor when the CD4 + level was less than 100 cells / μL, while when it was higher than 200 cells / μL, the treatment Significant effect. Conclusion: Taking anti-TB therapy for AIDS patients with pulmonary tuberculosis significantly improves the clinical symptoms and prolongs the survival time of patients with tuberculosis.